23
Aug
Aug
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is what the human record actually holds.
23
Aug
Aug
A plain-language look at what published animal research has studied about BPC-157 and the heart: bleeding, clotting, heart rhythm, and the aortic wall.
23
Aug
Aug
BPC-157 comes from a protein in human gastric juice. Plain-language look at the rat and tissue studies on the digestive tract, and what they do not show.
23
Aug
Aug
Published eye research on BPC-157 rests mainly on one 2023 review of glaucoma and other animal models. Here is what it covers, and what it does not.
23
Aug
Aug
A field-by-field walkthrough of a BPC-157 COA: the exact sequence, molecular weight, purity value, CAS number, and lot details a researcher should check.
23
Aug
Aug
What published research says about BPC-157 and the brain: one 2021 animal-model review, a 2026 pain-pathway review, and an honest look at how thin that record is.
23
Aug
Aug
A plain-language look at published BPC-157 blood vessel research, including the 2026 human artery tissue study, what ex vivo means, and what the studies do not show.
23
Aug
Aug
How standalone BPC-157 differs from the pre-mixed blends that contain it, what is in each vial, and why combining peptides is a research idea, not a proven bigger effect.
FDA letter 694608-12102024 cited Xcel Research LLC’s long GLP-1-class product list. Why catalog breadth is not verification — and what to check instead.
SwissChems was named in FDA’s December 10, 2024 warning-letter batch. How to read the letter itself — and how to vet a verification-first alternative.